Stealth transgenes enable CAR-T cells to evade host immune responses.
Korneel GrauwetTrisha R BergerMichael C KannHarrison SilvaRebecca C LarsonMark B LeickStefanie R BaileyAmanda A BouffardDavid MillarKathleen GallagherCameron J TurtleMatthew J FrigaultMarcela V MausPublished in: Journal for immunotherapy of cancer (2024)
Together, these data suggest that the proposed stealth transgenes may reduce the immunogenicity of autologous and allogeneic cellular therapeutics. Moreover, patient data indicate that repeated doses of autologous FMC63-based αCD19 CAR-T cells significantly increased the anti-CAR T cell responses in these patients.
Keyphrases
- bone marrow
- immune response
- end stage renal disease
- electronic health record
- ejection fraction
- newly diagnosed
- chronic kidney disease
- stem cell transplantation
- cell therapy
- big data
- peritoneal dialysis
- small molecule
- stem cells
- platelet rich plasma
- machine learning
- low dose
- inflammatory response
- data analysis
- patient reported